Tower Research Capital (TRC)’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Tower Research Capital (TRC)’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-44,275	Closed	-$13.2K	–	6470
2023 Q2	$13.2K	Buy	44,275 +19,977	+82%	+$6.03K	﹤0.01%	3796
2023 Q1	$10K	Buy	24,298 +11,753	+94%	+$9.03K	﹤0.01%	4451
2022 Q4	$15K	Buy	12,545 +5,972	+91%	+$9.73K	﹤0.01%	3469
2022 Q3	$15K	Buy	6,573 +4,862	+284%	+$12.7K	﹤0.01%	4194
2022 Q2	$4K	Sell	1,711 -1,064	-38%	-$7.38K	﹤0.01%	5305
2022 Q1	$27K	Buy	2,775 +2,450	+754%	+$22K	﹤0.01%	3268
2021 Q4	$3K	Sell	325 -785	-71%	-$7.8K	﹤0.01%	5542
2021 Q3	$11K	Buy	1,110 +979	+747%	+$9.6K	﹤0.01%	4279
2021 Q2	$1K	Buy	+131	New	+$1.28K	﹤0.01%	5308

Tower Research Capital (TRC)'s GRNA Position: Q3 2023 in Review

Tower Research Capital (TRC) sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 44,275 shares — an estimated $13.2K sold.

Tower Research Capital (TRC) first reported a position in GRNA in Q2 2021 and held it in 9 quarters. The position peaked at $27K in Q1 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Tower Research Capital (TRC) reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 44,275 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $13.2K.
Tower Research Capital (TRC) first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q2 2021 and held it in 9 quarters.
Tower Research Capital (TRC)'s GreenLight Biosciences Holdings, PBC Common Stock position peaked at $27K in Q1 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2023, filed 14 Nov 2023.